Stockreport

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

Oculis Holding AG  (OCS) 
PDF ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic ne [Read more]